The relevant detail is that the honest answer is that published stability data for these specific molecules in a research-grade presentation essentially does not exist, so what you get is extrapolation from the licensed formulations and from general peptide chemistry. That extrapolation is reasonable. It is still extrapolation.
Freeze-concentration is the mechanism people miss. As ice forms, everything that is not water is excluded into a shrinking unfrozen fraction, so the local concentration of peptide, buffer salts and preservative rises sharply. If the buffer components crystallise at different rates, local pH can shift by more than a unit. That is why a phosphate-buffered solution can behave badly on freezing while an unbuffered one is fine.
Worth being precise here: the temperature dependence is roughly Arrhenius over the range that matters, which in practice means every ten degrees of increase roughly doubles to triples the rate. Ten days at thirty degrees is therefore comparable to something on the order of a month or two at four degrees — bad, but not the catastrophe it feels like when you open a warm parcel.
Where community-submitted samples with known thermal excursions have been tested at Janoshik or Medutest, the recurring finding is that lyophilised material tolerates warm transit far better than intuition suggests, while reconstituted material shipped warm does not. The asymmetry is consistent enough to plan around.
One qualification: none of this addresses sterility. A vial can be chemically pristine and microbiologically compromised, and a chromatogram will not tell you which.
Store solid, store cold, store dry, and reconstitute what you will use rather than what fits in the vial.
I would gently push back on the second point — the evidence there is thinner than stated. – tess_amankwah 7 months ago Adding for future readers: the certificate should carry the lot number, not just a batch code. – tandem_gradient 9 months ago add a comment